In this issue:
- European consensus on vaccination in pwMS
- Botox for MS-related bladder symptoms
- PRLs are associated with more relapses and worse cognitive recovery after relapse
- Knowledge and worries about motherhood in women with MS
- Cladribine tablets vs fingolimod for highly active MS
- aHSCT vs fingolimod, natalizumab, and ocrelizumab in highly active RRMS
- Comparison of dimethyl fumarate, fingolimod, and ocrelizumab after natalizumab cessation
- Influence of oral tobacco and smoking on MS disease activity and progression
- Frequency of new asymptomatic MRI lesions in patients with NMOSD
- Does initial high efficacy therapy surpass an escalation treatment strategy?
Please login below to download this issue (PDF)